Organogenesis Hldgs Inc Stock Price, News & Analysis

Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q3 2020 net revenue of $100.8 million, up 57% from $64.3 million in Q3 2019, driven by a 66% increase in Advanced Wound Care products. The company achieved a net income of $20.9 million, a turnaround from a loss of $10.7 million in the prior year. Adjusted EBITDA was $24.6 million. Despite the COVID-19 pandemic, the company reaffirmed its 2020 financial guidance with expected revenues between $311 million and $314 million, representing a 20% year-over-year growth.

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its participation in the 2020 Symposium on Advanced Wound Care (SAWC), set for November 4-6. Key presentations include a study led by Dr. Oscar M. Alvarez highlighting Apligraf®'s effectiveness in treating pressure injuries. Additionally, the company will sponsor an Innovation Theater event discussing advanced wound care solutions. Attendees can engage with specialists at Organogenesis' virtual booth. The company's COO emphasized its commitment to advancing wound healing standards through evidence-based product offerings.

Organogenesis (Nasdaq: ORGO) reported preliminary Q3 2020 results with net revenue projected between $99.0 million and $100.0 million, marking a 54% to 56% increase from $64.3 million in Q3 2019. Advanced Wound Care products contributed $88.5 million to $89.3 million, up 63% to 64%, while Surgical & Sports Medicine products generated $10.5 million to $10.7 million, a 5% to 7% rise. The company's updated FY 2020 guidance estimates net revenue of $311 million to $314 million, with anticipated positive GAAP net income and adjusted EBITDA.

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced a change in its presentation schedule for the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The company will now present on September 21, 2020, at 2:30 p.m. Eastern Time, instead of the previously scheduled time of September 22, 2020, at 4:10 p.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for approximately 30 days post-event. Organogenesis specializes in regenerative medicine, providing solutions for advanced wound care and surgical needs.

Organogenesis Holdings, focused on regenerative medicine, will participate in two investor conferences. Management will engage in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16 at 5:00 p.m. ET, followed by another at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 4:10 p.m. ET. Live audio webcasts will be available on their Investor Relations webpage, with replays accessible for 30 days.

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the resignation of CFO Timothy M. Cunningham effective August 18, 2020. His departure was not due to disputes or financial issues. Henry Hagopian, previously Vice President of Finance, has stepped in as interim CFO while a national search for a permanent replacement begins. CEO Gary S. Gillheeney acknowledged Cunningham's role in the company's progress and public transition. Hagopian brings extensive financial experience, including previous roles at CIRCOR International and Lucent Technologies.

Organogenesis Holdings Inc. (ORGO) reported a net revenue of $69 million for Q2 2020, an increase of 6% year-over-year. Revenue from Advanced Wound Care products rose 8% to $59.7 million, while Surgical & Sports Medicine products declined by 5% to $9.2 million. The net loss improved to $5.2 million from $9.6 million in Q2 2019. Adjusted EBITDA was $274,000, up from a loss of $4.8 million. The company reinstated its 2020 revenue guidance for 5%-6% growth, reflecting strong operational fundamentals despite the COVID-19 pandemic.

Organogenesis Holdings (Nasdaq: ORGO) announces participation as a Platinum Sponsor at the 2020 Symposium on Advanced Wound Care (SAWC) Virtual Experience from July 24-26. The company's advanced wound care research, including products like Apligraf and Dermagraft, will be showcased. Highlights include an Innovation Theater event and multiple virtual Private Networking Suites for attendees to engage with experts. Key poster presentations cover studies on various wound treatments, including living cellular constructs and collagen dressings for venous leg ulcers.

Organogenesis Holdings Inc. (Nasdaq: ORGO) has scheduled its second quarter 2020 financial results announcement for August 10, 2020, after market close. A conference call will follow at 5:00 p.m. ET, providing updates and a question and answer session. Investors can join by dialing 866-795-3142 or via a live webcast on the company’s investor relations website. A replay will be available for two weeks. Organogenesis specializes in regenerative medicine products for Advanced Wound Care and Surgical markets.